Table 5.
Summary of prediction result of antivirals targeting each protein of HPV-16.
| HPV-16 protein | Number of antiviralsa | Example |
|---|---|---|
| Protein E7 | 7 | Docosanol targeting GP340 or GP350 protein of Epstein-Barr Virus has been approved to treat herpes labialis, fever blisters, etc |
| Regular Protein E2 | 5 | Voxilaprevir targeting NS3/4A protein of Hepatitis C Virus has been approved to treat chronic Hepatitis C caused by Hepatitis C Virus infection |
| Protein E6 | 6 | Telaprevir is an NS3/4A viral protease inhibitor. It has been approved to treat chronic Hepatitis C Virus infection in combination with other drugs |
| Minor capsid protein L2 | 4 | Grazoprevir targeting NS3/4A protein of Hepatitis C Virus has been approved to treat Hepatitis C viral infection |
| Protein E4 | 8 | Nelfinavir is a potent viral protease inhibitor for treating infections of Human Immunodeficiency Virus (HIV), and it targets the protease of HIV -1 |
| Probable protein E5 | 7 | Maraviroc is a chemokine receptor antagonist drug targeting C–C chemokine receptor type 5. It has been approved to treat HIV-1 infection |
| Replication protein E1 | 7 | Pirodavir (investigational drug) targets the genome polyprotein of Polioviruses and it seems to have broad-spectrum antiviral effects on multiple kinds of Human Rhinoviruses |
| Major capsid protein L1 | 5 | Docosanol targeting GP340 or GP350 protein of Epstein-Barr Virus has been approved to treat herpes labialis, fever blisters, etc |
| Protein E8^E2C | 7 | TMC-310911 (investigational drug) is a protease inhibitor targeting HIV-1 protease and it seems to have effect on treating HIV-1 infection |
a Indicating the number of antivirals which was predicted to have potential interaction with specific HPV-16 protein.